CAMBRIDGE, Mass., April 17, 2018 – Catabasis Pharmaceuticals, Inc. , a
clinical-stage biopharmaceutical company, today announced a restructuring of the organization to focus resources on the Company’s late-stage lead program, edasalonexent for the treatment of Duchenne muscular dystrophy (DMD). Catabasis is prioritizing this program to deliver against its goal of bringing a life changing therapy to those affected by Duchenne.
“This decision best positions us to achieve success with our most advanced program to help Duchenne patients and to support the long-term growth of Catabasis. However, on a personal
level, this decision was difficult and I want to thank the talented and dedicated colleagues who
are affected for their hard work and commitment to our mission,” said Jill C. Milne, Ph.D., Chief
Executive Officer of Catabasis. “Based on disease-slowing data from our MoveDMD trial, we
believe edasalonexent can make a significant difference in the lives of boys affected by Duchenne. These important corporate changes will allow us to focus our resources on continuing
to advance edasalonexent and improving the lives of boys affected by this devastating disease.”
For more on this decision, please see the full press release here.